Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera Sciencesâ management team are dedicated and focused to making Alimera a leading ophthalmic pharmaceutical company. Our team has demonstrated expertise through the extensive commercialization and development of ophthalmic products. Source
No articles found.
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company targeting the ...
Salarius Pharmaceuticals, Inc. is a clinical-st...
At Electromedical Technologies, we believe results speak louder than words. Since ...
At Electromedical Technologies, we believe resu...
Luna (NASDAQ:LUNA) develops and manufactures new-generation products for the healt...
Luna (NASDAQ:LUNA) develops and manufactures ne...
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical compan...
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clin...
Inovio is bringing IMMUNO-INGENUITY⢠to life and is reshaping the future of trea...
Inovio is bringing IMMUNO-INGENUITY⢠to life ...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
Kodiak Sciences is a clinical stage company developing innovative therapeutics to ...
Kodiak Sciences is a clinical stage company dev...
Join the National Investor Network and get the latest information with your interests in mind.